IDV vehicle
36E79726D0015
NEW AWARD FOR VENLAFAXINE HCL TABLETS WITH MARLEX PHARMACEUTICALS, INC. PERIOD OF PERFORMANCE IS 2/28/2026 - 2/27/2027 WITH 4 ONE-YEAR OPTION PERIODS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $4.1M |
| Start date | Feb 28, 2026 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 10, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 10, 2026 | P00002 | $0 | MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO THE CONTRACT. |
| Apr 27, 2026 | P00001 | $0 | CHANGE VENDOR POC FROM TRUDY NICKELSON TO BRIAN CURRENT 805-477-9866 X240 BCURRENT@GSMS.US |
| Jan 16, 2026 | 0 | $0 | NEW AWARD FOR VENLAFAXINE HCL TABLETS WITH MARLEX PHARMACEUTICALS, INC. PERIOD OF PERFORMANCE IS 2/28/2026 - 2/27/2027 WITH 4 ONE-YEAR OPTION PERIODS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.